Literature DB >> 16265339

Early reperfusion strategies after acute ST-segment elevation myocardial infarction: the importance of timing.

David P Faxon1.   

Abstract

Acute ST-segment elevation myocardial infarction is estimated to occur in more than 500,000 people in the US every year. With the introduction of reperfusion therapy by fibrinolysis or primary angioplasty, mortality has significantly fallen. Although fibrinolysis is more readily available than primary angioplasty, the latter is more effective and results in better short-term and long-term outcomes if performed in a timely manner by an experienced operator and hospital team. The ischemic time, door-to-balloon time and clinical risk are important determinants of favorable outcome. Primary angioplasty is the preferred reperfusion strategy when symptom onset is longer than 3 h, in high-risk patients, such as those with cardiogenic shock, congestive heart failure or elderly age, and those with contraindications for fibrinolysis. Primary angioplasty is the preferred strategy in interventional facilities, with a goal door-to-balloon time of less than 90 min. For patients who present to noninterventional facilities, transfer to a hospital capable of primary angioplasty is safe and effective if the additional treatment delay is less than 90 min. Facilitated percutaneous coronary intervention has been shown in several small trials to offer early vessel patency and improve outcomes compared with fibrinolysis alone, but has not been shown to reduce mortality. Larger trials are ongoing to evaluate the benefit of this approach. The establishment of an effective and efficient system for the rapid transport of patients to centers capable and experienced in primary angioplasty is severely needed to provide optimum treatment and outcomes to patients with ST-segment elevation acute myocardial infarction.

Entities:  

Mesh:

Year:  2005        PMID: 16265339     DOI: 10.1038/ncpcardio0065

Source DB:  PubMed          Journal:  Nat Clin Pract Cardiovasc Med        ISSN: 1743-4297


  6 in total

1.  Cardiac magnetic resonance with edema imaging identifies myocardium at risk and predicts worse outcome in patients with non-ST-segment elevation acute coronary syndrome.

Authors:  Subha V Raman; Orlando P Simonetti; Marshall W Winner; Jennifer A Dickerson; Xin He; Ernest L Mazzaferri; Giuseppe Ambrosio
Journal:  J Am Coll Cardiol       Date:  2010-06-01       Impact factor: 24.094

2.  Neuroprotective antioxidant STAZN protects against myocardial ischemia/reperfusion injury.

Authors:  James J Ley; Ricardo Prado; Jian Qin Wei; Nanette H Bishopric; David A Becker; Myron D Ginsberg
Journal:  Biochem Pharmacol       Date:  2007-09-08       Impact factor: 5.858

3.  Fibrinolysis vs. primary percutaneous coronary intervention for ST-segment elevation myocardial infarction cardiogenic shock.

Authors:  Saraschandra Vallabhajosyula; Dhiran Verghese; Malcolm R Bell; Dennis H Murphree; Wisit Cheungpasitporn; Paul Elliott Miller; Shannon M Dunlay; Abhiram Prasad; Gurpreet S Sandhu; Rajiv Gulati; Mandeep Singh; Amir Lerman; Bernard J Gersh; David R Holmes; Gregory W Barsness
Journal:  ESC Heart Fail       Date:  2021-03-11

4.  Control of fibrinolytic drug injection via real-time ultrasonic monitoring of blood coagulation.

Authors:  Dmitry A Ivlev; Shakhla N Shirinli; Konstantin G Guria; Svetlana G Uzlova; Georgy Th Guria
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

5.  Twelve-Lead Electrocardiogram Acquisition With a Patchy-Type Wireless Device in Ambulance Transport: Simulation-Based Randomized Controlled Trial.

Authors:  Sunyoung Yoon; Taerim Kim; Taehwan Roh; Hansol Chang; Sung Yeon Hwang; Hee Yoon; Tae Gun Shin; Min Seob Sim; Ik Joon Jo; Won Chul Cha
Journal:  JMIR Mhealth Uhealth       Date:  2021-04-01       Impact factor: 4.773

6.  Hemodynamic variables and mortality in cardiogenic shock: a retrospective cohort study.

Authors:  Christian Torgersen; Christian A Schmittinger; Sarah Wagner; Hanno Ulmer; Jukka Takala; Stephan M Jakob; Martin W Dünser
Journal:  Crit Care       Date:  2009-10-02       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.